ASBM Letter to Idaho Board of Pharmacy
August 6, 2014
The Idaho Board of Pharmacy held a hearing on August 5th and 6th regarding proposed regulations for the treatment of biosimilars in their state. View ASBM letter here.
wp_sysadmin
Senate HELP Committee authors letter to HHS Secretary on biosimilars issues
August 1, 2014
View letter here.
Pennsylvania has a chance to update its law to allow for biosimilar medicine substitutions – Pittsburgh Post Gazette
July 9, 2014
See article here.
June 2014 Newsletter
July 3, 2014
ASBM Shares EU Physician Survey in Paris Michael Reilly, Executive Director of the Alliance for Safe Biologic Medicines, (ASBM) was featured as an expert panelist at the “Understanding Biologic Medicine: Science, Regulatory Policy and the Changing Dynamics of Biosimilars” event hosted by AbbVie on June 10th in Paris, France. The two-part event was webcast worldwide […]
EU Approves First Biosimilar Insulin
July 1, 2014
On June 27, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) announced granting of preliminary marketing approval for the European Union’s first biosimilar insulin glargine product. Called Abasria (LY2963016), the investigational basal (long-acting) insulin is intended for the treatment of type 1 and type 2 diabetes. Abasria, like its reference product, the […]
Massachusetts Governor Signs Pharmacy Legislation Creating a Pathway for Biosimilars
June 24, 2014
Arlington, VA – Today, Governor Deval Patrick enacted biosimilars legislation updating Massachusetts’s pharmacy law and paving the way for the substitution of biosimilars deemed ‘interchangeable’ by the Food and Drug Administration (FDA). The Governor took such action after swift passage of HB 3724 in both chambers of the General Court of the Commonwealth of Massachusetts. […]
Dr. Dolinar Presents at DIA Annual Conference
June 19, 2014
On June 19th, ASBM Chairman Richard Dolinar, MD presented at the Drug Information Agency’s (DIA) 50th Annual Meeting in San Diego, California. “Trends in Biosimilars Regulation Within Developed and Emerging Markets” was an assessment of current debates within the regulatory landscape of biosimilars. Dr. Dolinar participated on a panel moderated by Andrew Robertson, Director of U.S. […]
May 2014 Newsletter
June 6, 2014
GaBI Publishes ASBM Whitepaper on European Prescriber Survey On June 5, The Generics and Biosimilars Initiative Journal published a paper authored by ASBM’s Chairman Richard Dolinar, MD and its Executive Director Michael Reilly. The paper is based on data collected by ASBM for its 2013 survey of 470 prescribing physicians with clinical experience using biologics […]
GaBI Publishes ASBM Whitepaper on European Prescriber Survey
June 5, 2014
On June 5, The Generics and Biosimilars Initiative Journal published a paper authored by ASBM’s Chairman Richard Dolinar, MD and its Executive Director Michael Reilly. The paper is based on data collected by ASBM for its 2013 survey of 470 prescribing physicians with clinical experience using biologics and biosimilars. Respondents included specialists from five Western […]
